title: Sitimagene ceradenovec, a gene therapeutic for the treatment of glioma.
abstract: Ark Therapeutics Group plc is developing sitimagene ceradenovec, a herpes simplex virus thymidine kinase/ganciclovir gene therapy utilizing an adenoviral vector, for the potential treatment of glioma. Sitimagene ceradenovec is currently undergoing a phase III clinical trial in malignant glioma patients.
authors.affiliation: University of the Pacific, Department of Microbiology, Arthur A Dugoni School of Dentistry, 2155 Webster Street, San Francisco, CA 94115, USA. nduzgune@pacific.edu
authors.forename: Nejat
authors.initials: N
authors.lastname: Düzgünes
mesh_terms: D000818:Animals; D001932:Brain Neoplasms / Q000628:therapy*; D000075202:Contraindications; D004353:Drug Evaluation, Preclinical; D015316:Genetic Therapy; D005910:Glioma / Q000628:therapy*; D006801:Humans; D013329:Structure-Activity Relationship; D013937:Thymidine Kinase / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D013937:Thymidine Kinase; C529697:sitimagene ceradenovec